Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Authors :: Mathew Vithayathil
Antonio D'Alessio
Claudia A. M. Fulgenzi
Naoshi Nishida
Martin Schönlein
Johann von Felden
Kornelius Schulze
Henning Wege
Anwaar Saeed
Brooke Wietharn
Hannah Hildebrand
Linda Wu
Celina Ang
Thomas U. Marron
Arndt Weinmann
Peter R. Galle
Dominik Bettinger
Bertram Bengsch
Arndt Vogel
Lorenz Balcar
Bernhard Scheiner
Pei‐Chang Lee
Yi‐Hsiang Huang
Suneetha Amara
Mahvish Muzaffar
Abdul Rafeh Naqash
Antonella Cammarota
Nicola Personeni
Tiziana Pressiani
Matthias Pinter
Alessio Cortellini
Masatoshi Kudo
Lorenza Rimassa
David J. Pinato
Rohini Sharma
Source :: Liver International. 42:2538-2547
Publication Year :: 2022
Publisher :: Wiley, 2022.
Abstract: Background and Aims Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. Methods 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age

Full Text Access

Tools